UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Endoscopic retrograde cholangiopancreatography (ERCP) is a widespread technique used for the treatment of different diseases of the bile and pancreatic ducts. The technique is, however, associated with rare but potentially severe morbidity. Some of the adverse events associated with ERCP are directly linked to commonly made mistakes and can, therefore, be prevented. Here, we discuss 10 common and/or high-impact mistakes that are made during ERCP and how they can be avoided.

Mistakes in endoscopic retrograde cholangiopancreatography and how to avoid them

Mistakes in endoscopic retrograde cholangiopancreatography and how to avoid them

Thierry Ponchon, Jerome Rivory, Mathieu Pioche

Topics

Endoscopy Hepatobiliary Pancreas

Citation

Pioche M, Rivory J and Ponchon T. Mistakes in endoscopic retrograde cholangiopancreatography and how to avoid them. UEG Education 2016: 16: 24–26.

Published

2024
UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Cholangioscopy is a minimally invasive, endoscopic technique that allows direct visualisation of the bile ducts, facilitating both diagnostic and therapeutic interventions. It is a useful tool in managing biliary diseases, allowing characterisation and tissue acquisition for strictures of undetermined aetiology, facilitating extension assessment for biliary cancer and providing intraductal lithotripsy for complex biliary stones.

Mistakes in cholangioscopy and how to avoid them

Mistakes in cholangioscopy and how to avoid them

Marianna Arvanitakis, Malina Wiesand, Paraskevas Gkolfakis

Published

2025
UEG Presentation
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Summary: Autoimmune disease of liver and bile ducts

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Summary: Autoimmune disease of liver and bile ducts

Christian Lange 1

1 Klinikum rechts der Isar, München, Germany

Event

UEG Postgraduate Teaching Programme Berlin 2025

Topics

Hepatobiliary Immunology

Session

Autoimmune disease of liver and bile ducts

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025
UEG Podcast Episode
UEG Podcast
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Best of UEG Week 2024 with Pilar Acedo Nunez and Juozas Kupcinskas on "Bench to Bedside"

Pilar Acedo, Juozas Kupcinskas, Julia Mayerle

Published

2024
UEG Poster
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Introduction

Clostridioides difficile infection (CDI) is the leading cause of hospital-acquired infectious diarrhoea in adults and is associated with significant morbidity and mortality1,2. A review by Mitchell and Gardner3 showed all-cause mortality of up to 30% in the first 30 days of contracting CDI. According to the European Society of Clinical Microbiology and Infectious Disease ‘the most important problem in treating CDI is the high recurrence rate’, with up to 25% having a recurrence of C. diff, and 40-65% of those patients going on to have a second recurrence4. As per NICE guidelines, vancomycin is currently the first line treatment for CDI with fidaxomicin reserved for relapses and recurrences5.

Aims & Methods

Objective: To determine to what extent Fidaxomicin is superior to Vancomycin in reducing relapse of CDI.
Methods: A retrospective audit was conducted on 464 adult community and inpatients with CDI at the Norfolk and Norwich University Hospital from the 1/6/23 to 1/6/24. Data collection included patient demographics, episodes of CDI, treatment response and risk factors such as immunosuppression. A relapse is defined as a repeat episode of CDI occurring within 12 weeks of previous symptom resolution, while a recurrence is an episode occurring after 12 weeks.

Results

In total, 464 patients who had a positive C diff. toxin gene result were reviewed. Excluded were 103 patients who were not given antibiotics, 72 patients who no information was available and 14 who received an alternative antibiotic, e.g. metronidazole. 221 patients received vancomycin and 54 received fidaxomicin. 4/54 patients who received fidaxomicin went on to relapse (7.4%), one of which subsequently had extended pulsed fidaxomicin. 50/221 receiving vancomycin had a relapse (22.6%). The odds ratio for relapse rate of vancomycin versus fidaxomicin was 3.65, 95% CI 1.26 to 10.61. A student t-test result was 3.33 with p-value 0.0011.

Conclusion

The data shows a significantly lower relapse rate in high-risk patients treated with fidaxomicin compared to vancomycin for CDI. Reconsideration of first line therapy for high-risk patients with continuing care under the MDT team, for example at the Norfolk and Norwich University Hospital during the C. Diff ward round, is essential to ensure appropriate treatment is offered.

References

  1. Vindigni, S. M., & Surawicz, C. M. (2015). C. difficile Infection: Changing Epidemiology and Management Paradigms. Clinical and translational gastroenterology, 6(7), e99. https://doi.org/10.1038/ctg.2015.242.
  1. Wilcox MH, Ahir H, Coia JE, et al. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. J Antimicrob Chemother. 2017;72(9):2647-2656. doi:10.1093/jac/dkx1743.
  1. Mitchell, B.G., Gardner, A. Mortality and Clostridium difficile infection: a review. Antimicrob Resist Infect Control 1, 20 (2012). https://doi.org/10.1186/2047-2994-1-20
  1. Bauer(2009), Meehan(2016), Sheitoyan-Pesant (2016)
  1. Clostridioides difficile infection: antimicrobial prescribing (2021) Nice Guideline NG199
REDUCING RELAPSE RATES IN C. DIFFICILE: IS FIDAXOMICIN THE BETTER OPTION?

REDUCING RELAPSE RATES IN C. DIFFICILE: IS FIDAXOMICIN THE BETTER OPTION?

Demetra Kyriakides 1, James Cleaver 1, Alvin Ochieng 1

1 Norfolk and Norwich University Hospital, Norfolk, United Kingdom

Conference

UEG Week Berlin 2025

Topics

Oesophagus

Submission format

Abstract

Session

OESOPHAGEAL, GASTRIC AND DUODENAL (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025
UEG Presentation
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Palliative endoscopy: How to get the best of all worlds (ERCP, EUS, PTC)

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Palliative endoscopy: How to get the best of all worlds (ERCP, EUS, PTC)

Ilaria Tarantino 1

1 ISMETT, Palermo, Italy

Event

UEG Postgraduate Teaching Programme Berlin 2025

Topics

Digestive Oncology Endoscopy Hepatobiliary Surgery

Session

Cholangiocarcinoma secrets unveiled

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025
UEG Presentation
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
ENDOSCOPIC INTERMUSCULAR DISSECTION FOR EARLY GASTRIC CANCER WITH SEVERE SUBMUCOSAL FIBROSIS

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Introduction

Severe submucosal fibrosis (SSF) in early gastric cancer (EGC) is known to cause technical difficulty for endoscopic resection.1, 2 Various methods have been reported to tackle this problem. However, there is no established consensus on the management of this situation. Endoscopic intermuscular dissection (EID) has been successfully used in the rectum to overcome SSF.3 The procedure involves the dissection between the circular and longitudinal layers of the muscularis propriae. Recently, the procedure has been used in the stomach for en bloc resection of a neuroendocrine tumor.4 We report a case endoscopic resection of early gastric cancer with severe submucosal fibrosis where EID was used to attain a negative vertical margin.

Aims & Methods

We aim to demonstrate the use of EID in the stomach to overcome the challenge of SSF in endoscopic resection of early cancer. An 81 year male underwent an upper endoscopy for heaviness and discomfort in the epigastrium for few months. It revealed an approximately 25mm lesion around a healed ulcer scar at the gastric angle on the lesser curvature side with irregular surface and vascular pattern and a clear demarcation line. Biopsy showed high grade dysplasia and endoscopic resection was planned. Since the lesion was over a healed ulcer scar, and endoscopy showed convergence of gastric folds towards the lesion, SSF was expected. The resection was started by conventional endoscopic submucosal dissection in retroflexion and a tunnel was created under the distal side of the tumor. However, after the incision and initial submucosal dissection, we encountered SSF. We decided to carefully dissect in the intermuscular plane underneath the fibrotic area by identifying and separating the circular and longitudinal muscle layer. Similar method was used on the oral side where EID was performed after initial ESD and tunnel was completed. Resection was accomplished and the circular muscle defect in the middle of the ulcer was closed with multiple endoclips.

Results

Total procedure time was 60 minutes. En bloc specimen measured 56mm x 40mm. There were no immediate or early complications. Patient was started on soft diet on post procedure day 1 and discharged on day 5. Pathology was tubular adenoma with high grade dysplasia. Horizontal and vertical margins were negative and specimen contained the muscle layer.

Conclusion

This case demonstrates the feasibility of EID in the stomach without any special accessories or equipment. EID can be used to overcome severe submucosal fibrosis in early gastric cancer. Further studies on wider applicability of gastric EID in clinical practice would be worthwhile.

References

  1. Jeong JY, Oh YH, Yu YH et al. Does submucosal fibrosis affect the results of endoscopic submucosal dissection of early gastric tumors?. Gastrointestinal endoscopy. 2012 jul 1;76(1):59-66.
  2. Higashimaya M, Oka S, Tanaka S et al. Outcome of endoscopic submucosal dissection for gastric neoplasm in relationship to endoscopic classification of submucosal fibrosis. Gastric Cancer. 2013 Jul;16:404-10.
  3. Toyonaga T, Ohara Y, Baba S et al. Peranal endoscopic myectomy (PAEM) for rectal lesions with severe fibrosis and exhibiting the muscle-retracting sign. Endoscopy. 2018 aug;50(08):813-7.
  4. Despott EJ, Lucaciu LA, Murino A et al. First report of gastric endoscopic intermuscular dissection. Endoscopy. 2024 Dec;56(S 01):E132-3.

ENDOSCOPIC INTERMUSCULAR DISSECTION FOR EARLY GASTRIC CANCER WITH SEVERE SUBMUCOSAL FIBROSIS

Darshan Parekh 1, Nao Takeuchi 2, Shunya Takayanagi 2, Yoshiaki Kimoto 2, Yohei Minato 2, Hideyuki Chiba 3, Ken Ohata 2

1 Mumbai Institute of Gastroenterology, Mumbai, India

2 NTT Medical Center Tokyo, Tokyo, Japan

3 Omori Red Cross Hospital, Tokyo, Japan

Event

UEG Week Vienna 2024

Topics

Oesophagus

Submission format

Video Case

Session

Video Cases

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.